We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: Abbott’s Psoriasis Treatment May Need More Analyses, Trials
FDA: Abbott’s Psoriasis Treatment May Need More Analyses, Trials
January 19, 2011
Abbott Laboratories has withdrawn its biologics license application and EU marketing authorization application for its psoriasis treatment briakinumab after regulatory authorities indicated more trials may be necessary.